Article Contents ::
- 1 The Brand Name CITALOP Has Generic Salt :: Citalopram
- 2 CITALOP Is From Company EAST WEST Priced :: Rs. 104.9
- 3 CITALOP have Citalopram is comes under Sub class Anti Depressants of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Depressants
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CITALOP Has Generic Salt :: Citalopram
CITALOP Is From Company EAST WEST Priced :: Rs. 104.9
CITALOP have Citalopram is comes under Sub class Anti Depressants of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Depressants
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Depressive illness, Bipolar disorder, Panic disorder, Substance abuse disorders, Alcohol dependence, Anxiety disorders including obsessive-compulsive disorder and social phobia, Post-traumatic stress disorder, Premenstrual syndrome, Idiopathic Parkinson’s disease and Eating disorder.
Drug Dose ::
Adult: Initially, 20 mg daily, increased to 40 mg once daily after at least 1 wk or 60 mg daily if necessary. Hepatic impairment: Recommended dose: 20 mg daily. Oral Depressive phase of bipolar disorder: Adult: Initially, 20 mg daily, increased to 40 mg once daily after at least 1 wk or 60 mg daily if necessary. Hepatic impairment: Recommended dose: 20 mg daily. Oral Panic disorder with or without agoraphobia: Adult: Initially, 10 mg daily, increased to 20 mg daily after 1 wk. Max: 60 mg daily. Hepatic impairment: Recommended dose: 20 mg daily. Special Populations: Patients with reduced hepatic function should receive dosages of no more than 30 mg/day. Elderly maximum 40 mg daily.
Hypersensitivity, concomitant admin with MAOIs or within 14 days of discontinuing MAOI treatment; children and adolescents <18 yr; treatment of depressive illness; lactation. Drug Precautions ::
Caution should be taken in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders, hepatic and renal impairment. Abrupt withdrawal of Citalopram should be avoided. Gradual discontinuation of treatment if patient enters into manic phase; pregnancy. Increased risk of hyponatraemia and SIADH. May reduce convulsant threshold thus, citalopram should be used with care in epileptic patients.
Drug Side Effects ::
Increased sweating, headache, tremor, fatigue, asthenia, dizziness, abnormal accommodation, somnolence, insomnia, agitation, nervousness, nausea, dry mouth, constipation, diarrhoea, palpitation, rash, pruritus, abnormal vision, decreased libido, anxiety, increased appetite, anorexia, apathy, impotence, suicide attempt, confusion, yawning, dyspepsia, vomiting, abdominal pain, flatulence, increased saliva, weight decrease or increase, postural hypotension, tachycardia, rhinitis, ejaculation failure, fatigue, extrapyramidal disorders.Potentially Fatal: Increased risk of suicidal thinking and behaviour especially in child and adolescents. Monitor closely for signs of clinical worsening, suicidality or unusual changes in behaviour.
Pregnancy category ::
Drug Mode of Action ::
Citalopram is bicyclic phthalane derivative and a selective serotonin re-uptake inhibitor, w/ little or no effect on noradrenaline, dopamine and GABA re-uptake. The inhibitory activity explains the antidepressant property of citalopram. It has no or very low affinity for 5-HT1AA, 5-HT2A, D1 and D2 receptors, ?1, ?2, ?-adrenergic, histamine H1, muscarinic, cholinergic, benzodiazepine and opioid receptors.
Drug Interactions ::
May increase anticoagulant effect w/ drugs affecting haemostatis (e.g. warfarin). Increased risk of hypomania w/ sibutramine. Increased lowering seizure threshold w/ TCAs and other SSRIs. Potentially Fatal: Increased risk of severe adverse effects (e.g. serotonin syndrome) w/ MAOI. QT interval prolongation w/ subsequent risk of torsade de pointes w/ QT-prolonging drugs (e.g. pimozide, quinidine, procainamide, chlorpromazine, thioridazine, amiodarone, sotalol, moxifloxacin, pentamidine, levomethadyl, methadone).